The cancer neoantigen vaccine can induce specific CD4+ and CD8+ T cells to target specific patient tumours, and in further clinical trials, it is expected that the effect of the vaccine will be satisfactory (Ott et al., 2017). The gene discussed is CD8A; the disease is cancer.